Free Trial

Exagen (XGN) Competitors

Exagen logo
$7.00 -0.18 (-2.51%)
Closing price 04:00 PM Eastern
Extended Trading
$7.02 +0.01 (+0.21%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XGN vs. CSTL, LFMD, CELC, OMDA, FTRE, AUNA, TALK, SBC, EHAB, and AIRS

Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Castle Biosciences (CSTL), LifeMD (LFMD), Celcuity (CELC), Omada Health (OMDA), Fortrea (FTRE), Auna (AUNA), Talkspace (TALK), SBC Medical Group (SBC), Enhabit (EHAB), and AirSculpt Technologies (AIRS). These companies are all part of the "healthcare" industry.

Exagen vs. Its Competitors

Castle Biosciences (NASDAQ:CSTL) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Castle Biosciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Castle Biosciences currently has a consensus target price of $37.00, indicating a potential upside of 123.70%. Exagen has a consensus target price of $7.50, indicating a potential upside of 7.14%. Given Castle Biosciences' higher probable upside, equities research analysts plainly believe Castle Biosciences is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Exagen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 6.5% of Castle Biosciences shares are owned by insiders. Comparatively, 12.6% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Castle Biosciences had 4 more articles in the media than Exagen. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Exagen. Castle Biosciences' average media sentiment score of 0.89 beat Exagen's score of 0.63 indicating that Castle Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Exagen
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Castle Biosciences has a net margin of -1.46% compared to Exagen's net margin of -27.34%. Castle Biosciences' return on equity of 3.41% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-1.46% 3.41% 2.95%
Exagen -27.34%-133.69%-34.87%

Castle Biosciences has higher revenue and earnings than Exagen. Castle Biosciences is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$332.07M1.44$18.25M-$0.19-87.05
Exagen$55.64M2.68-$15.11M-$0.84-8.33

Summary

Castle Biosciences beats Exagen on 11 of the 15 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XGN vs. The Competition

MetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$152.93M$10.25B$5.54B$9.41B
Dividend YieldN/A2.06%3.75%4.03%
P/E Ratio-8.3311.7121.0120.09
Price / Sales2.6830.03433.8199.01
Price / CashN/A22.3936.1658.27
Price / Book12.963.578.125.65
Net Income-$15.11M$235.43M$3.25B$257.91M
7 Day Performance0.14%-1.67%0.97%2.09%
1 Month Performance-4.89%2.91%7.36%11.13%
1 Year Performance262.69%-16.44%31.31%18.40%

Exagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XGN
Exagen
3.1505 of 5 stars
$7.00
-2.5%
$7.50
+7.1%
+250.2%$152.93M$55.64M-8.33220News Coverage
CSTL
Castle Biosciences
2.2 of 5 stars
$19.46
-4.1%
$37.00
+90.1%
-10.4%$586.11M$332.07M-102.42540News Coverage
Positive News
LFMD
LifeMD
2.5677 of 5 stars
$12.20
-2.4%
$12.00
-1.6%
+64.4%$568.09M$212.45M-35.88230Positive News
CELC
Celcuity
1.9651 of 5 stars
$13.34
-3.3%
$28.40
+112.9%
-24.3%$522.18MN/A-4.4040
OMDA
Omada Health
N/A$18.67
+0.2%
$23.57
+26.3%
N/A$479.72MN/A0.00849Quiet Period Expiration
FTRE
Fortrea
3.7229 of 5 stars
$4.45
-14.8%
$15.00
+237.1%
-81.6%$472.41M$2.70B-0.5115,500Gap Up
AUNA
Auna
3.5084 of 5 stars
$6.25
-1.3%
$10.70
+71.3%
-28.1%$468.50M$1.17B10.7714,842
TALK
Talkspace
3.7513 of 5 stars
$2.65
-4.3%
$4.50
+69.8%
+15.1%$463.46M$187.59M132.57500News Coverage
Positive News
SBC
SBC Medical Group
N/A$4.51
+0.9%
N/AN/A$463.14M$205.42M0.00N/ANews Coverage
Positive News
EHAB
Enhabit
3.4276 of 5 stars
$7.31
-4.4%
$8.75
+19.7%
-31.0%$387.38M$1.03B-2.6410,700News Coverage
AIRS
AirSculpt Technologies
1.2934 of 5 stars
$5.39
-0.2%
$3.75
-30.4%
+25.1%$317.41M$180.35M-17.97240Positive News

Related Companies and Tools


This page (NASDAQ:XGN) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners